Acyclic Nitrogen Bonded Directly To The -c(=x)- Group Patents (Class 546/169)
-
Publication number: 20090306133Abstract: The present invention relates to Acetyl Coenzyme A Carboxylase (ACC) inhibitors according to formula (I), or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, E, L, Z and n are as defined herein, to processes for preparing such compounds, to pharmaceutical compositions containing them, to the use of such inhibitors and to methods for their therapeutic use, particularly in the treatments of obesity and diabetes mellitus.Type: ApplicationFiled: December 19, 2008Publication date: December 10, 2009Applicant: ASTRAZENECA ABInventors: David Blomberg, Anders Holmen, Petra Johannesson, Pernilla Sorme, Pernilla Stahlberg, Kay Brickmann, Volker Schnecke, Eric Wellner, Ragnar Hovland, Asa Mansson, Alleyn Plowright
-
Publication number: 20090306112Abstract: The invention is related to compounds of Formula I or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.Type: ApplicationFiled: July 19, 2007Publication date: December 10, 2009Applicant: Gilead Sciences, Inc.Inventors: Carina E. Cannizzaro, James M. Chen, Manoj C. Desai, Michael L. Mitchell, Sundaramoorthi Swaminathan, Lianhong Xu, Zheng-Yu Yang
-
Publication number: 20090286828Abstract: The present invention relates to compounds of formula (I), or to salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.Type: ApplicationFiled: December 21, 2005Publication date: November 19, 2009Inventors: Andrea Bozzoli, Clive Leslie Branch, Jacqueline Anne Macritchie, Howard Robert Marshall, Roderick Alan Porter, Simone Spada
-
Patent number: 7619091Abstract: The present invention relates to a method for the treatment, amelioration and/or prophylaxis of a neurological condition, in particular neurodegenerative disorders which comprises the administration of an effective amount of a compound of formula (I): to a subject in need thereof. The present invention also relates to a compound of formula (II) and processes for its preparation.Type: GrantFiled: July 16, 2003Date of Patent: November 17, 2009Assignee: Prana Biotechnology LimitedInventors: Kevin Jeffrey Barnham, Elisabeth Colette Louise Gautier, Gaik Beng Kok, Guy Krippner
-
Publication number: 20090253740Abstract: This invention provides a compound of the formula (I): And their use for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition comprising the above compound.Type: ApplicationFiled: July 2, 2007Publication date: October 8, 2009Inventors: Tadashi Kawashima, Satoshi Nagayama, Kazunari Nakao, Hirotaka Tanaka
-
Patent number: 7598236Abstract: Compounds of formula I pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.Type: GrantFiled: December 15, 2007Date of Patent: October 6, 2009Assignee: Abbott LaboratoriesInventors: Michael R. Schrimpf, Karin R. Tietje, Richard B. Toupence, Jianguo Ji, Anwer Basha, William H. Bunnelle, Jerome F. Daanen, Jennifer M. Frost, Kevin B. Sippy
-
Patent number: 7572913Abstract: Substituted piperidine compounds represented by the structure I are provided, wherein each of R1a, R1b, R1c, R1d, R1e, R1f, R1g, R1h, R2, R2A, R3, R4, A, X, a, x and n is as defined in the specification. Substituted piperidine compounds of structure I may permeate or penetrate across a nerve cell membrane into the interior of a nerve cell, may inhibit intracellular Rho kinase enzyme found in nerve cells in mammals, and may find utility in repair of damaged nerves in the central and peripheral nervous system of such mammals. These compounds may induce the regeneration or growth of neurites in mammalian nerve cells and may thereby induce regeneration of damaged or diseased nerve tissue. These compounds also find additional utility as antagonists of the enzyme Rho kinase in treatment of disease states in which Rho kinase is implicated.Type: GrantFiled: February 24, 2005Date of Patent: August 11, 2009Assignee: Bioaxone Therapeutique Inc.Inventors: Lisa McKerracher, Eryk Thouin, William Lubell, Robert Snow, Karine Gingras
-
Publication number: 20090192146Abstract: The present invention provides substituted di-, tri-, tetra- and penta-sulfide compounds and compositions, and methods of using the same for the treatment and/or prevention of a cell proliferative disorder. The present invention also provides methods for preparing trisulfide compounds and compositions.Type: ApplicationFiled: February 9, 2009Publication date: July 30, 2009Applicant: ACEA BIOSCIENCES, INC.Inventors: Xiao XU, Haoyun An, Xiaobo Wang
-
Publication number: 20090192175Abstract: Novel heteroaromatic compounds of formula (I): wherein A1, A2, A3, R1, R2, G1, G2, Q1 and Q2 are as defined in claim 1; or salts or N-oxides thereof. Furthermore, the present invention relates to processes for preparing compounds of formula (I), to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to methods of using them to combat and control insect, acarine, mollusc and nematode pests.Type: ApplicationFiled: April 25, 2007Publication date: July 30, 2009Applicant: SYNGENTA CROP PROTECTION, INC.Inventors: Pierre Jung, Patricia Durieux, William Lutz, Peter Maienfisch, Thomas Pitterna, Peter Renold, Werner Zambach
-
Publication number: 20090186918Abstract: There is provided compounds of formula (I) wherein W is an optionally substituted aryl or heteroaryl group, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.Type: ApplicationFiled: October 27, 2006Publication date: July 23, 2009Inventors: Benjamin Pelcman, Andrei Sanin, Peter Nilsson, Hasse Kromann
-
Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides
Publication number: 20090181968Abstract: The present invention relates to compounds of formula (I) [Chemical formula should be inserted here. Please see paper copy] as well as pharmaceutically acceptable salts and pharmaceutical compositions including the compounds are prepared or thereof: wherein, A1, A2, R1, R2, R3, R4, and R5 and n are as defined in the specification. The compounds of formula (I) are useful in therapy.Type: ApplicationFiled: November 22, 2006Publication date: July 16, 2009Applicant: ASTRAZENECA ABInventors: Kosrat Amin, Johan Broddefalk, Yantao Chen, Karolina Nilsson, Claire Milburn, Helene Desfosses, Ziping Liu, Maxime Tremblay, Christopher Walpole, Zhong-yong Wei, Hua Yang -
Publication number: 20090163543Abstract: One aspect of the invention relates to HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided. The invention also provides methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.Type: ApplicationFiled: December 19, 2008Publication date: June 25, 2009Applicant: Georgetown UniversityInventors: Alan P. Kozikowski, Bin Chen
-
Publication number: 20090163523Abstract: The invention provides a pharmaceutical combination comprising: a) at least one S1P receptor agonist, and b) at least one JAK3 kinase inhibitor and a method for treating or preventing autoimmune diseases or cell, tissue or organ graft rejection using such a combination.Type: ApplicationFiled: May 2, 2005Publication date: June 25, 2009Inventor: Philip Lake
-
Publication number: 20090143429Abstract: The present invention relates to substituted quinoline derivatives of Formula (I); wherein hal, n, A, formula (a), R1, R2, R3, R4, R5 and R6 are defined herein, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-2 and/or neurokinin-3 (NK-3) receptors. These compounds can thus be used in methods of treatment to suppress and treat such disorders.Type: ApplicationFiled: July 25, 2006Publication date: June 4, 2009Inventors: James Michael Crawforth, Brian John Williams
-
Publication number: 20090142297Abstract: This invention relates to 5-substituted isoindoline compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.Type: ApplicationFiled: May 30, 2008Publication date: June 4, 2009Inventors: George W. Muller, Roger Shen-Chu Chen, Alexander L. Ruchelman
-
Patent number: 7541466Abstract: Tetrahydroisoquinoline derivatives, pharmaceutical compositions comprising them and methods of treating disease are disclosed herein. The disclosed compounds are useful in the treatment and prevention of diseases mediated by chloride channel activity and/or protein trafficking, including, but not limited to, diseases associated with impaired mucociliary clearance such as cystic fibrosis, bronchitis, emphysema, and the like.Type: GrantFiled: December 7, 2004Date of Patent: June 2, 2009Assignee: Genzyme CorporationInventors: Marko J. Pregel, Bradford H. Hirth, John L. Kane, Jr., Shuang Qiao, Jill Gregory, Lisa Cuff
-
Publication number: 20090131444Abstract: The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm blooded animals such as humans.Type: ApplicationFiled: May 23, 2006Publication date: May 21, 2009Applicant: ASTRAZENECA ABInventors: Folkert Reck, Marshall Morningstar, Hajnalka Hartl
-
Patent number: 7534891Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof as well as to pharmaceutical compositions comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.Type: GrantFiled: October 14, 2005Date of Patent: May 19, 2009Assignee: Hoffman-La Roche Inc.Inventors: Silvia Gatti McArthur, Cornelia Hertel, Matthias Heinrich Nettekoven, Susanne Raab, Hans Richter, Olivier Roche, Rosa Maria Rodriguez-Sarmiento, Franz Schuler
-
Publication number: 20090124629Abstract: The present invention relates to novel compounds of formula (I) or pharmaceutically acceptable salt thereof: wherein G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl and indazolyl; p is an integer ranging from 0 to 5; R1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R5; each R2 is independently hydrogen, fluorine or C1-4alkyl; n is 2, 3, 4, or 5; R3 is C1-4alkyl; R4 is hydrogen, or a C1-4alkyl group, a benzyl group, a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5;or R4 is a —SR6 group; R5 is selected from a group consisting of: isoxazolyl, —CH2—N-pyrrolyl, 1,1-dioxido- 2-isothiType: ApplicationFiled: April 12, 2006Publication date: May 14, 2009Inventors: Giorgio Bonanomi, Anna Checchia, Elettra Fazzolari, Dieter Hamprecht, Fabrizio Michel, Luca Tarsi, Silvia Terreni
-
Patent number: 7531535Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.Type: GrantFiled: December 13, 2007Date of Patent: May 12, 2009Assignee: Bristol-Meyers Squibb CompanyInventors: Donald J. P. Pinto, Jennifer X. Qiao
-
Patent number: 7524883Abstract: The present invention provides compounds having formula (1): wherein R1-R6, A, J, D, E, G, Q, w, x, y, and z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of cancer and/or inflammatory disorders, and more generally as proteasome inhibitors.Type: GrantFiled: January 8, 2003Date of Patent: April 28, 2009Assignee: Eisai R&D Management Co., Ltd.Inventors: Sergei Agoulnik, Kozo Akasaka, Frank Fang, Jean-Christophe Harmange, Lynn Hawkins, Yimin Jiang, Charles Johannes, Xiang-Yi Li, Pamela McGuiness, Erin A. Murphy, Shawn Schiller, Mary Vermeulen, Jiayi Wu
-
Publication number: 20090105279Abstract: The invention is related to compounds of Formula I: or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.Type: ApplicationFiled: July 19, 2007Publication date: April 23, 2009Inventors: Carina E. Cannizzaro, James M. Chen, Manoj C. Desai, Michael L. Mitchell, Sundaramoorthi Swaminathan, Lianhong Xu, Zheng-Yu Yang
-
Patent number: 7517988Abstract: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.Type: GrantFiled: November 14, 2007Date of Patent: April 14, 2009Assignee: Pharmacyclics, Inc.Inventors: Erik J. Verner, Hon C. Hui
-
Patent number: 7511061Abstract: A prodrug, N-oxide, addition salt, quaternary amine or stereochemically isomeric form thereof, wherein L1 and L2 are R1—Y— wherein each (R1—Y)— substituent is defined independently of the other; Y is C1-4alkanediyl, C2-4alkenediyl, C2-4alkynediyl, C(?O), or a direct bond; R1 is hydrogen, cyano, aryl or a substituted or unsubstituted C1-14heterocycle; =Z1-Z2=Z3- represents a radical of formula ?N—N?CH— (a-1), ?N—CH?N— (a-2), ?CH—N?N— (a-3); X is SO2, (CH2)n wherein n is 1 to 4, C(?O), C(?S), or a direct bond; R2 is aryl, C3-7cycloalkyl, C3-7cycloalkyl substituted with one or more substituents independently selected from hydroxy, aryl, aryloxy, a substituted or unsubstituted C1-14heterocycle, C3-7cycloalkyl, hydroxycarbonyl, C1-6alkyloxycarbonyl, hydroxyC1-6alkyl, hydroxyC1-6alkyloxy, hydroxyC1-6alkylthio and arylC1-6alkylthio, C1-12alkyl or C1-12alkyl substituted with one or more substituents independently selected from hydroxy, aryl, aryloxy, a substituted or unsubstituted C1-14heterocycle, C3-7cycloalkyl, hyType: GrantFiled: June 2, 2005Date of Patent: March 31, 2009Assignee: Janssen Pharmaceutica N.V.Inventors: Ashis Kumar Saha, David William End, Bart Lieven Daniel De Corte, Henry Joseph Breslin, Li Liu
-
Publication number: 20090082372Abstract: The present invention relates to arylmethylene substituted N-Acyl-?-amino alcohols of the formula I in which Y is selected from the aryl or heteroaryl groups: and R1, R2, R3, R4, R5, Q, X and W have the meaning as defined in the description. The compounds according to the invention are effective FSH antagonists and can be used for example for fertility control in men or in women, or for the prevention and/or treatment of osteoporosis.Type: ApplicationFiled: July 24, 2008Publication date: March 26, 2009Inventors: Lars WORTMANN, Marcus Koppitz, Bernd Menzenbach, Dirk Kosemund, Norbert Schmees, Hans-Peter Muhn, Thomas Frenzel, Florian Peter Liesener, Anna Schrey, Ronald Kuehne
-
Publication number: 20090054440Abstract: The present invention relates to substituted quinoline hydrazides of Formula (I): wherein R1, R2, R3, R4, R5, X, Y and Z are defined herein, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-2 and/or neurokinin-3 (NK-3) receptors. These compounds can thus be used in methods of treatment to suppress and treat such disorders.Type: ApplicationFiled: May 5, 2006Publication date: February 26, 2009Inventors: William Robert Carling, Jason Matthew Elliott, Elena Mezzogori, Michael Geoffrey Neil Russell, Brian John Williams
-
Publication number: 20090048226Abstract: The present invention relates to novel classes of compounds which are caspase inhibitors, in particular interleukin-1? converting enzyme (“ICE”) inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting caspase activity and consequently, may be advantageously used as agents against interleukin-1-(“IL-1”), apoptosis-, interferon-? inducing factor-(IGIF), or interferon-?-(“IFN-?”) mediated diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to methods for inhibiting caspase activity and decreasing IGIF production and IFN-? production and methods for treating interleukin-1, apoptosis-, and interferon-?-mediated diseases using the compounds and compositions of this invention.Type: ApplicationFiled: January 22, 2008Publication date: February 19, 2009Inventors: Marion W. Wannamaker, Guy W. Bemis, Paul S. Charifson, David J. Lauffer, Michael D. Mullican, Mark A. Murcko, Keith P. Wilson, James W. Janetka, Robert J. Davies, Anne-Laure Grillot, Zhan Shi, Cornelia J. Forster
-
Patent number: 7491827Abstract: The present invention provides compounds of general formula I: or a pharmaceutically acceptable salt thereof, wherein R1, X, Z, R2, X1, Ar, n, R3 and R4 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR8 and accordingly are useful for the treatment of a variety of inflammatory and allergic disorders.Type: GrantFiled: July 14, 2004Date of Patent: February 17, 2009Assignee: Millennium Pharmaceuticals, Inc.Inventors: Mingshi Dai, Bing Guan, Robert A. Bennett, Douglas F. Burdi, Shomir Ghosh, Gang Li, Charles Minor, Tracy J. Jenkins
-
Patent number: 7482458Abstract: NK3 receptor antagonists of formula (I): are useful in treating inter alia pulmonary disorders, CNS disorders and neurodegenerative disorders.Type: GrantFiled: March 21, 2006Date of Patent: January 27, 2009Assignee: SmithKline Beecham Farmaceutica S.p.A.Inventors: Carlo Farina, Giuseppe Arnaldo Maria Giardina, Mario Grugni, Luca Francesco Raveglia
-
Publication number: 20080312277Abstract: The present invention relates to a method for identifying a glycemic stabilizing compound by: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is modulated, where a modulation in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound. In addition, the invention relates to a method for identifying a glycemic stabilizing compound, comprising: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is increased, wherein an increase in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound. Further, the invention relates to a method for identifying a glycemic stabilizing compound, comprising: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is decreased, wherein a decrease in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound.Type: ApplicationFiled: November 1, 2005Publication date: December 18, 2008Inventors: James N. Leonard, Zhi Liang Chu, Marc A. Bruce, P. Douglas Boatman
-
Publication number: 20080293765Abstract: Compounds of Formula I wherein R1, A, R2, R3, R4, R5, R8, n, m, q and r are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.Type: ApplicationFiled: December 11, 2006Publication date: November 27, 2008Inventors: Jeffrey Albert, Cristobal Alhambra, James Kang, Gerard Koether, Thomas Simpson, James Woods, Yan Li
-
Publication number: 20080293727Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.Type: ApplicationFiled: December 12, 2007Publication date: November 27, 2008Inventors: Roger D. Tung, Mark A. Murcko, Govinda Rao Bhisetti
-
Publication number: 20080287493Abstract: The present invention relates to arylmethylen substituted N-acyl-Y-aminoalcohols of the general formula I in which Q, X, W, R1, R2, R3, R4 and R5 have the meaning as defined in the description. The compounds according to the invention are effective FSH modulators and can be used for example for fertility regulation in men or in women.Type: ApplicationFiled: April 24, 2008Publication date: November 20, 2008Inventors: Lars Wortmann, Bernd Menzenbach, Marcus Koppitz, Dirk Kosemund, Hans-Peter Muhn, Anna Schrey, Ronald Kuhne, Thomas Frenzel, Florian Peter Liesener
-
Publication number: 20080280949Abstract: Compounds of Formula I wherein R1, A, R2, R3, R4, R5, n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.Type: ApplicationFiled: August 10, 2006Publication date: November 13, 2008Applicant: AstraZeneca ABInventors: Jeffrey S. Albert, Cristobal Alhambra, James Kang, Gerard M. Koether, Thomas R. Simpson, James Woods, Yan Li
-
Publication number: 20080275083Abstract: The present invention relates to 2,3,4,9-tetrahydro-1H-carbazoles of the general formula I, in which Q, X, W, R1, R2, R3, R4 and R5 have the meaning as defined in the description. The compounds according to the invention are effective FSH antagonists and can be used for example for fertility control in men or in women, or for the prevention and/or treatment of osteoporosis.Type: ApplicationFiled: March 26, 2008Publication date: November 6, 2008Inventors: Lars Wortmann, Marcus Koppitz, Hans Peter Muhn, Thomas Frenzel, Florian Peter Liesener, Anna Schrey, Ronald Kuehne
-
Publication number: 20080269206Abstract: The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-6 or encompassed by formulas I-VI) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.Type: ApplicationFiled: March 28, 2008Publication date: October 30, 2008Inventors: Michael Geoffrey Neil Russell, Huw David Vater, Jacqueline Anne Macritchie, Kevin James Doyle, David Brown, Joanne Peach
-
Publication number: 20080261945Abstract: The present invention relates to compounds of formula (I), a pharmaceutically acceptable salt, solvate or prodrug thereof: wherein R1 is phenyl optionally substituted by 1, 2 or 3 halogen atoms which halogen atoms may be the same or different; R2 is C1-6alkyl, C3-6cycloalkyl or acetyl; X is oxygen or sulphur; a is 1, 2 or 3; b is 0 or 1; c is 0, 1 or 2; R3 is hydrogen or C1-6alkyl; R4 is hydrogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxyC1-6alkyl, C3-6cycloalkyl or C3-6cycloalkylC1-6alkyl; R5 is hydrogen; or R5 and R3, together with the interconnecting atoms, form a 4, 5 or 6 membered ring; R6 is phenyl or thienyl, either of which is optionally substituted by 1, 2 or 3 halogen atoms, which atoms may be the same or different; and z is 0, 1 or 2; wherein when z is 1 or 2, Z is a halogen atom, and wherein when z is 2 the halogen atoms may be the same or different.Type: ApplicationFiled: November 10, 2005Publication date: October 23, 2008Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Paul William Smith, Paul Adrian Wyman
-
Publication number: 20080255095Abstract: A compound of the formula (I): wherein R1 is C1-C6 alkyl, amino, (C1-C6 alkyl)amino, di(C1-C6 alkyl)amino or a nitrogen-containing saturated heterocyclic; R2 and R3 are hydrogen or C1-C6 alkyl; Arom is phenyl, idenyl, napthyl, phenanthrenyl, furyl, thiolyl, pyrrolyl, azepinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3 oxadiazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or quinolyl; A is C1-C6 alkylene; Ra is hydrogen, C1-C6 alkyl or C2-C6 alkenyl; E is a single bond, oxygen, sulfur or —NR4—, wherein R4 is hydrogen or C1-C7 alkanoyl; X1 and X2 are oxygen or sulfur; or a pharmacologically acceptable salt or ester thereof.Type: ApplicationFiled: June 18, 2007Publication date: October 16, 2008Applicant: BTG INTERNATIONAL LIMITEDInventors: Kazuo Koyama, Shinji Marumoto, Narihiro Toda, Hiroshi Kogen, Keiko Suzuki
-
Publication number: 20080255189Abstract: A compound of the following formula: in which R1, R2, R3, U, V, T, W, X, Y, Z, m, n, p, x, y, and z are as defined herein. Also disclosed are (1) a pharmaceutical composition containing such a compound, and (2) a method for treating Hepatitis C virus infection using such a compound.Type: ApplicationFiled: March 26, 2008Publication date: October 16, 2008Applicant: National Health Research InstitutesInventors: Jyh-Haur Chern, Tsu-An Hsu, Iou-Jiun Kang, Li-Wen Wang, Chung-Chi Lee, Yen-Chun Lee, Yu-Sheng Chao
-
Publication number: 20080234269Abstract: Compounds of Formula I wherein R1, A, R2, R3, R4, R5, n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.Type: ApplicationFiled: September 19, 2006Publication date: September 25, 2008Applicant: ASTRAZENECA ABInventors: James B. Campbell, Jeffrey S. Albert, Cristobal Alhambra, James Kang, Gerard M. Koether, Thomas R. Simpson, James Woods, Yan Li
-
Publication number: 20080234319Abstract: The invention provides compounds of formula (I), processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy, wherein R1, R2, R3 and n are as defined in the specificationType: ApplicationFiled: March 21, 2008Publication date: September 25, 2008Inventors: Simon David Guile, Mark Ebden
-
Publication number: 20080214605Abstract: Compounds of Formula I wherein R1, A, R2, R3, R4, R5, n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.Type: ApplicationFiled: September 19, 2006Publication date: September 4, 2008Applicant: AstraZeneca ABInventors: Jeffrey S. Albert, Gerard M. Koether, Cristobal Alhambra, James Kang, Thomas R. Simpson, James Woods, Yan Li
-
Publication number: 20080200504Abstract: Compounds of Formula (I) wherein R1, A, R2, R3, R4, R5,n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.Type: ApplicationFiled: August 9, 2006Publication date: August 21, 2008Applicant: AstraZeneca ABInventors: Jeffrey S. Albert, Cristobal Alhambra, James Kang, Gerard M. Koether, Thomas R. Simpson, James Woods, Yan Li
-
Publication number: 20080200500Abstract: Compounds of Formula I wherein R1, A, R2, n, R3, m, R5 and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.Type: ApplicationFiled: May 30, 2006Publication date: August 21, 2008Applicant: AstraZeneca ABInventors: Thomas R. Simpson, James Kang, S. Jeffrey Albert, Cristobal Alhambra, M. Gerard Koether, M. James Woods, Yan Li
-
Patent number: 7381738Abstract: The present application describes modulators of MCP-1 of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein X, Z, a, b, c, d, n, R1, R2, R3, R4, R5, R10, R10a, and R12, are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using modulators of formula (I) are disclosed.Type: GrantFiled: February 17, 2005Date of Patent: June 3, 2008Assignee: Bristol-Myers Squibb CompanyInventors: Douglas G. Batt, Percy H. Carter
-
Publication number: 20080113977Abstract: The present invention provides a compound of the formula: (Formula I); or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient, and methods for treating physiological disorders, particularly congestive heart disease, comprising administering to a patient in thereof an effective amount of a compound of Formula I.Type: ApplicationFiled: November 12, 2003Publication date: May 15, 2008Inventors: Arindam Chatterjee, Theodore Goodson Jr, Mary Margaret Mader, John Eldon Toth
-
Publication number: 20080103173Abstract: The present invention relates to compounds of formula (I), a pharmaceutically acceptable salt or solvate thereof: wherein n, m and p, which may be the same or different, are either 0 or 1. Also disclosed are processes for their preparation, pharmaceutical compositions containing them and their use as medicaments particularly in treating disorders of the central nervous system (CNS).Type: ApplicationFiled: November 10, 2005Publication date: May 1, 2008Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Roderick Alan Porter, Paul William Smith
-
Patent number: 7358359Abstract: Antibacterial compounds of formula I are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.Type: GrantFiled: July 22, 2005Date of Patent: April 15, 2008Assignee: University of WashingtonInventors: Niels H. Andersen, Jason Bowman
-
Publication number: 20080045568Abstract: Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.Type: ApplicationFiled: August 16, 2006Publication date: February 21, 2008Inventors: Yongqi Deng, Patrick J. Curran, Gerald W. Shipps, Lianyun Zhao, M. Arshad Siddiqui, Janeta Popovici-Muller, Jose S. Duca, Alan W. Hruza, Thierry O. Fischmann, Vincent S. Madison, Rumin Zhang, Charles W. McNemar, Todd W. Mayhood, William T. Windsor, Emma M. Lees, David A. Parry
-
Patent number: 7321063Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.Type: GrantFiled: February 24, 2004Date of Patent: January 22, 2008Assignee: Vertex Pharmaceuticals IncorporatedInventors: Roger D Tung, Mark A Murcko, Govinda R Bhisetti